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Abstract: Protein misfolding and aggregation cause a large number of neurodegenerative diseases in humans due to (i) gain 
of function as observed in Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and Prion’s disease or (ii) loss 
of function as observed in cystic ﬁ  brosis and α1-antitrypsin deﬁ  ciency. These misfolded proteins could either lead to the 
formation of harmful amyloids that become toxic for the cells or to be recognized and prematurely degraded by the protein 
quality control system. An increasing number of studies has indicated that some low-molecular-weight compounds named 
as chemical chaperones can reverse the mislocalization and/or aggregation of proteins associated with human conformational 
diseases. These small molecules are thought to non-selectively stabilize proteins and facilitate their folding. In this review, 
we summarize the probable mechanisms of protein conformational diseases in humans and the use of chemical chaperones 
and inhibitors as potential therapeutic agents against these diseases. Furthermore, recent advanced experimental and theo-
retical approaches underlying the detailed mechanisms of protein conformational changes and current structure-based drug 
designs towards protein conformational diseases are also discussed. It is believed that a better understanding of the mecha-
nisms of conformational changes as well as the biological functions of these proteins will lead to the development and design 
of potential interfering compounds against amyloid formation associated with protein conformational diseases.
Keywords: misfolding, Alzheimer’s disease, Prion’s disease, Parkinson’s disease, Huntington’s disease, amyloid, chemical 
chaperone, molecular dynamics simulation, structure-based drug design, protein conformational disease
Protein Conformational Diseases
Protein misfolding is believed to be the primary cause of several neurodegenerative diseases in humans, 
such as Alzheimer’s disease (AD), Creutzfeldt-Jakob disease, Gaucher’s disease, Huntington’s disease, 
Parkinson’s disease, Prion’s disease, cystic ﬁ  brosis (CF), α1-antitrypsin deﬁ  ciency, and many others. 
In most of the cases, protein misfolding takes place due to an undesirable mutation in the polypeptide 
chain, an unfavorable physiological environment or, in a few cases, some less known reasons.
The misfolded protein may lead to harmful effects, which can be divided into two categories (see 
Fig. 1 for details): (i) gain of function as observed in AD, Huntington’s disease, Parkinson’s disease, and 
Prion’s disease and (ii) loss of function as in the cases of CF and α1-antitrypsin deﬁ  ciency.
1 In the former 
category, the misfolded proteins may further aggregate to form amyloids, which ﬁ  nally cause cell toxic-
ity and eventually death. More than twenty proteins in humans are involved in aberrant aggregation, 
include Aβ, prion, β2-microglobulin, tau, α-synuclein, etc. Aggregation can also occur in proteins with 
native conformations, although mutations usually accelerate this process. In other words, mutations are 
not an absolute requirement for protein misfolding and diseases. In the latter category, mutations are 
associated with defect in folding, leading to the accumulation of intermediate structure in endoplasmic 
reticulum (ER), as a consequence of increasing ER stress.
2 Moreover, such mutations lead to the absence 
of the correctly folded proteins, resulting in the loss of some physiologically important functions.40
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Protein Quality Control System: 
Molecular Chaperones and Ubiquitin 
Proteasome System
Proteins that are not able to reach their native states 
are recognized as misfolded and subsequently 
targeted to a degradation pathway (Fig. 1C). This 
is referred to the “protein quality control” system, 
which plays a critical role in cell function and 
survival and consists of two components: molecu-
lar chaperones and ubiquitin-proteasome pathway 
(UPP).
3
Many molecular chaperones aid in normal fold-
ing of proteins and also in refolding of the abnor-
mal conformations back to their native states, thus 
prevent the formation of misfolded or aggregated 
structures (Fig. 1A and L) and slow, arrest, or revert 
disease progression.
1 They are capable of distin-
guishing between the native and non-native states 
of the targeted proteins. However, until now, it is 
still unclear how they distinguish between the cor-
rectly and incorrectly folded proteins and how they 
selectively target the latter for degradation. Molec-
ular chaperones further facilitate to direct the 
misfolded proteins to the proteasomal pathway 
(Fig. 1I). Abnormal proteins can also be targeted 
to proteasome for degradation by covalent attach-
ment to polyubiquitin, which is an energy-requiring 
process (Fig. 1C).
4
However, in some cases, the protein quality 
control system is imperfect (Fig. 1F). There are 
two types of protein quality control defect, which 
have been linked to the etiology of an increasing 
list of congenital and acquired conformational 
diseases. In the ﬁ  rst type, it is possible that the 
misfolded proteins are stable folding intermediates, 
thus they can escape from the degradation pathway 
and accumulate as aggregates, resulting in the 
formation of ﬁ  brilar deposits known as amyloids. 
In the second type, proteins harboring modest 
mutations not compromising their functional integ-
rity may be recognized as misfolded, resulting in 
unnecessary degradation and consequently leading 
to the loss of functional phenotypes.
From Protein Misfolding and 
Aggregation to Amyloid Fibrils
Protein misfolding and aggregation
Protein misfolding and its pathogenic conse-
quences have become an important research topic 
over the past decades. It is now well known that 
the molecular basis of protein aggregation into 
amyloid structures involves the existence of the 
misfolded forms of proteins (Fig. 1G and H). 
However, the critical problem is what factors are 
responsible for protein conformational changes 
leading to the misfolded forms. Over the past few 
years, a number of factors, such as mutations that 
destabilize the folded structure (Fig. 1H), changes 
in the environmental conditions (pH, oxidative 
stress, and metal ions), and the activity of certain 
proteins collectively named pathological chaper-
ones (apolipoprotein E, amyloid P component, and 
protein X), have been identiﬁ  ed to play such a 
critical role.
5 Once a certain concentration of the 
misfolded protein is reached, the formation of their 
aggregates can occur in the cells (Fig. 1J and K), 
leading to the formation of an amyloid-like struc-
ture, which eventually causes different types of 
neurodegenerative disorders and ultimately leads 
to cell death.
3
The formation of an aggregate is a common 
feature of all protein conformational diseases 
(PCDs). It is caused by the destabilization of the 
α-helical structures and the simultaneous forma-
tion of the β-sheet structures (Fig. 1G and H).
6 
These β-sheet structures are formed between alter-
nating peptide strands. Linkages between these 
strands result from hydrogen bonding between 
their aligned pleated structures.
7 Such β-linkages 
with a pleated strand from one molecule inserting 
into a pleated sheet of the next lead to the formation 
of intermolecular hydrogen bonding networks.
Before oligomerization, the ﬁ  brillogenesis often 
starts with dimers, which have been recognized as 
the initial building blocks of amyloid fibrils 
(Fig. 1J).
8 They further polymerize into oligomers 
(Fig. 1K). During this nucleation process, the 
content of the secondary β-structure of the oligo-
meric assemblies is generally increased.
9 After the 
nucleation or seeding step, the growing assemblies, 
ordered prefibrillar aggregates or protofibrils 
(Fig. 1M), are formed via an elongation process and 
eventually give rise to mature amyloid ﬁ  brils.
10
The relationship between protein 
misfolding and aggregation
Until now, it is still not clear whether conforma-
tional changes induce protein oligomerization and 
whether misfolding triggers protein aggregation.
11 
Based on the kinetic model of protein aggregation, 41
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Figure 1. The pathway of protein synthesis and degradation in the cell. (A) Nascent polypeptide chain is converted into its native folded 
protein with the help of molecular chaperones. (B) Nascent polypeptide chain with a mutation (blue ball) folds into its native-like protein 
(or partial unfolded protein). (C) Mutant (or partial unfolded) protein may be re-recognized as imperfect proteins, leading to ubiquitination by 
E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). (D) Misfolded protein enters into the protea-
some system with the help of the ubiquitin complex. (E) Misfolded protein is degraded into small peptide by proteasome and ubiquitin is 
regenerated. (F) Impaired proteasome system could not degrade the misfolded protein. (G) Native protein molecule is converted into mis-
folded structure, which is caused by destabilization of the α-helical structure and the simultaneous formation of the β-sheet structure. 
(H) Mutations accelerate protein misfolding. (I) Molecular chaperones facilitate to direct the misfolded proteins to the proteasomal pathway. 
(J) Misfolded monomers aggregate into dimer as initial building blocks for the formation of amyloid ﬁ  brils. (K) These building blocks further 
polymerize to form oligomers. (L) Molecular chaperones disaggregate the compact aggregates and develop native folded monomer. 
(M) Oligomers further form photoﬁ  brils. (N) Amyloid hypothesis. (O) Channel hypothesis.42
Zhao et al
Perspectives in Medicinal Chemistry 2007:1 
it has been proposed that the critical event in PCDs 
is the formation of protein oligomers that can act 
as the seeds to induce protein misfolding. In this 
model, misfolding occurs as a consequence of 
aggregation (polymerization hypothesis),
11 which 
follows a crystallization-like process dependent on 
nucleus formation.
An alternative model indicates that the underlying 
protein is stable in both the folded and misfolded 
forms in solution (conformation hypothesis).
5 It sug-
gests that spontaneous or induced conformational 
changes result in the formation of the misfolded 
protein, which may or may not form an aggregate. 
Several factors, such as those mentioned above, may 
cause the protein conformational changes and further 
lead to the misfolded forms of proteins.
In the third hypothesis, the native proteins 
undergo slightly conformational changes, resulting 
in the formation of an unstable amyloidogenic 
intermediate in the cellular environment. This 
unstable intermediate exposes many of its hydro-
phobic regions, leading to the growth of small 
oligomers, which mainly consist of β-sheets via 
intermolecular interactions. These small oligomers 
further form an ordered ﬁ  bril-like structure named 
amyloid also via intermolecular interactions. In 
this model, the conversion of the folded protein 
into the pathological form is triggered by confor-
mational changes, but the complete misfolding is 
dependent on oligomerization.
11 So far, most of 
the experimental ﬁ  ndings can be explained by the 
above three models. However, the conformation/
oligomerization hypothesis is still the most 
comprehensive and accepted model for protein 
misfolding and aggregation.
Amyloid aggregates lead to cell toxicity
Two hypotheses have been proposed to explain 
how the aggregates cause toxic effects to the cells 
(Fig. 1N and O). The ﬁ  rst one, known as the “amy-
loid hypothesis” (Fig. 1N),
9 directly believes that 
the huge amount of aggregates may damage organs 
simply by hindering a proper ﬂ  ow of nutrient to 
the cells, thus impairing tissue functions in the case 
of the peripheral amyloidosis. Recent studies have 
reported that an important role of modiﬁ  cation to 
the intracellular free calcium and reactive oxygen 
species (ROS) occurs in cells exposed to toxic 
aggregate.
12 It suggests that the oxidative stress 
following exposure to the early species involved 
in amyolid formation could damage cells and 
eventually cause cell death. However, it is still not 
clear why protein aggregation is followed by the 
production of ROS.
The second one, the so-called “channel hypoth-
esis” (Fig. 1O), has been proposed to explain the 
biochemical mechanism of amyloid toxicity.
13 This 
hypothesis also supports the changes of intracel-
lular ion content and ROS state mentioned above. 
Protoﬁ  brils, the precursors of longer protoﬁ  laments 
and mature ﬁ  brils, typically appear as globular 
assemblies (2.5–5 nm in diameter) with a high 
β-sheet content and spontaneously organize into 
beaded chains and variously sized annular rings 
comprising small “doughnut” shaped species form-
ing a central pore in membranes.
14 It is still not 
possible to detect these channels in the cells 
involved in amyloid diseases due to the technical 
difficulties, but channels have been observed 
in vitro from a number of amyolid peptides and 
proteins, including islet amyloid polypeptide (IAPP 
or Amylin), a neurotoxic fragment of the prion 
protein (PrP106–126), serum amyloid A, polygluta-
mine, transthyretin (TTR), α-synuclein, and lyso-
zyme. The observation of channels amongst such 
a diverse variety of peptide sequences suggests a 
deep underlying similarity in their physical chem-
ical structures. This special amyloid pore may 
account for the toxicity of the amyloid aggregates. 
Thus, protein oligomers may act as a biological 
signal killing the target cells by forming non-
speciﬁ  c membrane pores, which further result in 
the unbalance of the ion concentration.
Toxic Amyloid Formation Causes 
Many Human Neurodegenerative 
Disorders: The Cases of AD 
and Prion’s Disease
AD and prion disease are the primary and frequent 
discovered diseases involving selective neuronal 
vulnerability with degeneration in speciﬁ  c brain 
regions and deposits of the corresponding misfolded 
protein in neurons and other cells. In this section, 
we aim to elucidate the causes of human neurode-
generative disorders through the formation of toxic 
amyloids by the cases of AD and Prion’s disease.
Alzheimer’s disease
AD is a progressive neurodegenerative disease 
characterized by extracellular amyloid plaques and 
intraneuronal ﬁ  brillary tangles in the brain. It has 43
Chemical chaperone and inhibitor discovery
Perspectives in Medicinal Chemistry 2007:1 
been shown that Aβ1–40 and Aβ1–42 are the main 
alloforms of amyloid β (Aβ) peptides found in 
amyloid plaques. Aβ peptides are derived from 
proteolytic processing of the amyloid precursor 
protein (APP). APP can be cleaved by three differ-
ent proteases, named α-, β-, and γ-secretases. In 
general, β-secretase cleaves the extracellular 
domain of APP to generate the N terminus of Aβ, 
while γ-secretase performs proteolysis in the 
middle of the transmembrane domain of APP to 
produce the C terminus of Aβ.
15 Finally, the two 
main products, Aβ1–40 and Aβ1–42, migrate outside 
the cell and give rise to ﬁ  brils.
Several mechanisms have been proposed to 
explain the neuron toxicity of Aβ peptides, such 
as the formation of ion channels on the cell mem-
brane,
16 the generation of free radicals,
17 and the 
interaction of Aβ peptides with various receptors, 
such as apolipoprotein E
18 and mitochondrial 
hydroxyacyl-CoA dehydrogenase.
19 However, the 
cytotoxic mechanism of Aβ has not yet been fully 
understood at present. Compelling evidences have 
demonstrated that the soluble oligomers (amyloid-
derived diffusible ligands; ADDLs) and ﬁ  brils of 
Aβ are the toxic identities that cause neuronal 
injury and death in patients suffering from AD.
20
Prion’s disease
The prion protein is thought to cause a disease in 
cattle called bovine spongiform encephalopathy 
(BSE) or “mad cow disease” and a disease in 
human named variant Creutzfeldt-Jakob disease 
(vCJD).
5 It is known that normal prion protein is 
protease sensitive, soluble, innocuous, and has a 
high α-helical content. This protein is thought to 
undergo a conformational change in which 
α-helices of the wild-type protein PrP
C (normal 
cellular form) are converted into β-sheet-dominant 
PrP
SC (pathogenic isoform), resulting in misfolding 
and aggregation. PrP
C and PrP
SC share the same 
covalent structure but possess different folds. PrP
SC 
has been identiﬁ  ed as the causative agent in trans-
missible spongiform encephalopathies because it 
is capable of aggregating into a variety of forms 
from amorphous to highly structured aggregates.
A central theme in prion disease research is the 
detection of the process underlying the conforma-
tional transition from PrP
C to PrP
SC. PrP
C has been 
found to undergo a pH-dependent conformational 
change in the range of pH 4.4–6.0, with a loss of 
α-helical content and a gain of β-structure.
21 PrP
SC 
also acts as a template for the structural conversion 
of PrP
C as well as huntingtin proteins, subsequently 
forming aggregates.
22 Moreover, unlike AD, it is 
believed that in Prion’s disease, the conformational 
infection and aggregation can take place both 
extracellularly and intracellularly.
23
Protein Misfolding with the Loss 
of Function Lead to Several Lethal 
Diseases: The Case of CF
The human cystic ﬁ  brosis transmembrane conduc-
tance regulator (CFTR) gene encodes an integral 
membrane glycoprotein of 1,480 amino acid resi-
dues with two N-linked glycosylation sites.
24 The 
CFTR is a cAMP-regulated chloride (Cl
−) channel 
localized at the apical membrane of secretory 
epithelia. Mutations in this channel cause CF, a 
disease characterized by the inability of epithelial 
cells to secrete chloride, result in the production 
of thick and viscous mucus that causes severe 
functional obstruction of lungs and pancreas. 
A majority of CF patients has a deletion of a phe-
nylalanine residue at position 508, resulting in an 
F508del-CFTR protein.
25 The clinical importance 
of this mutation becomes evident because it 
accounts for 90% of patients diagnosed with CF.
26 
This mutation results in a misfolded channel retain-
ing in the ER in an immature state and are rapidly 
degraded by a process involving the ubiquitin-
dependent proteasomal system.
24 Thus very little 
of this protein can reach the cellular membrane, 
resulting in the loss of function phenotype.
Potential Treatments for PCDs
Drugs against PCDs in humans aim to inhibit 
aggregation and/or to enable the mutant proteins 
to escape from the protein quality control systems 
so that their function can be rescued. Recently, 
several low-molecular-weight compounds, named 
chemical chaperones,
27 have been shown to act as 
the potential therapeutic agents for the control of 
many PCDs. In this section, we provide some 
evidences showing that chemical chaperones or 
inhibitors can be used as potential therapeutic 
agents for the control of several PCDs in humans, 
such as AD, Prion’s disease, and CF.
Potential treatment for AD
Aβ has emerged as the most promising target in 
the treatment or prevention of AD. Inhibition of 44
Zhao et al
Perspectives in Medicinal Chemistry 2007:1 
Aβ-ﬁ  bril formation might be a reasonable therapeutic 
strategy because familial mutations that lead to an 
increase in Aβ concentration or to its aggregation 
increase neuropathology.
28 Unfortunately, no effec-
tive therapy using a chemical chaperone system has 
been successfully conducted so far. A previous study 
has shown that osmolytes such as glycerol and tri-
methylamine N-oxide (TMAO), acting as chemical 
chaperones, correct folding defects by preferentially 
hydrating partially denatured proteins and entropi-
cally stabilize native conformations.
29 Such infor-
mation could potentially be used to develop cellular 
models of Aβ aggregation and the assessment of 
agents that modulate ﬁ  bril formation. In this case, 
chemical chaperones could exacerbate the patho-
physiologic state. However, a variety of chemical 
compounds have been found to inhibit the ﬁ  brilla-
tion of Aβ, including antibiotics, benzofuran 
derivatives, sulfonated dyes, styryl benzene, ﬂ  avone, 
and peptidic β-sheet breakers. Cell culture experi-
ments have indicated that Aβ inhibitors could reduce 
the cytotoxicity of Aβ peptides and the amount of 
amyloid deposition in mice with acute amyloidosis.
30 
However, very few of them have entered into clinic 
trial phases because of the problems inherent in these 
inhibitors, including low bioavailability, poor 
biostability, toxicity, and inability across the blood-
brain barrier (BBB), limiting their therapeutic 
applications. Thus, structural modification of 
inhibitors as well as design of new inhibitors with 
alternative structural scaffolds is necessary to 
improve the physiochemical properties of these 
compounds in the future.
Potential treatment for Prion’s disease
Therapeutic agents are often designed in an attempt 
to destroy the PrP
SC structure and hopefully recov-
ery the PrP
C structure or any other innocuous 
isoform. For example, several β-sheet breaker 
peptides, which could slow or reverse disease 
progression, have been designed to disrupt the 
β-rich amyloidgenic PrP
SC species. However, it has 
been shown that disrupting PrP
SC is not sufﬁ  cient 
to inhibit Prion’s disease and that this strategy may 
increase propagation of PrP
SC and infectivity.
31 
Thus, strategies for stabilizating the PrP
C conforma-
tion also appear as alternative approaches.
Some chemical chaperons, such as TMAO, 
dimethyl sulfoxide (DMSO), and glycerol, are 
thought to stabilize the PrP
C conformation and 
have been suggested to be effective in the 
destruction/protection strategy. In a previous 
study, Tatzelt and co-workers have shown that 
TMAO and other protective osmolytes success-
fully prevent scrapie formation in vitro.
32 More-
over, a number of other compounds, such as 
anthracyclines, porphyrins, and diazo dyes, have 
also been shown to inhibit prion replication when 
administered with PrP
SC in animal models.
33 It is 
regretful that this is not a clinically relevant model 
for therapeutic intervention because subclinical 
disease exists for months in mice and years in 
humans.
7 However, a recent study by Vogtherr and 
co-workers has suggested that quinacrine binds 
speciﬁ  cally to PrP
C and inhibit the conversion of 
PrP
C to PrP
Sc, which in turn suppresses the pro-
gression of Creutzfeldt-Jacob disease.
34 Currently, 
quinacrine has been clinically approved and 
clinical trials are being carried out to test the use-
fulness of this molecule in patients suffering from 
Creutzfeldt-Jacob disease.
Potential treatment for CF
There are numerous ongoing efforts towards 
ﬁ  nding agents that promote the folding or block 
the degradation of nascent F508del-CFTR with 
the potential to provide a therapeutic basis for 
the treatment of CF. For example, Sato et al. have 
examined the effect of glycerol on the fate of the 
mutant F508del-CFTR and concluded that 10% 
glycerol (vol/vol) could mediate an increase in the 
transport of the mutant protein from the ER to the 
plasma membrane in a cell culture model, which 
is associated with an increase in the functional 
activity of CFTR.
35 In addition, two other low-
molecular-weight organic compounds, deuterated 
water and TMAO, have also been shown to 
increase the post-translational maturation of 
F508del-CFTR in a cell culture model, leading to 
the increase of the chloride transport activity.
36 
Moreover, other study has also reported that chlo-
ride transport is increased signiﬁ  cantly by the use 
of DMSO on polarized epithelial cell lines express-
ing F508del-CFTR.
37 These results all suggest that 
these low-molecular-weight compounds could 
stabilize this mutant, promoting the proper folding 
and transport to its site of function.
The role of chemical chaperones 
in the treatment for PCDs
Until now, the precise mechanisms of the action 
of chemical chaperones are still not fully 45
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understood. However, they are thought to provide 
positive effect on protein folding, to reduce protein 
aggregation, and to stabilize a conformation 
capable of escaping from the degradation pathway. 
For example, osmolytes, such as glycerol, are 
believed to stabilize the native structures of 
proteins, which can be explained by their prefer-
ential exclusion from the surfaces of proteins. This 
effect increases the chemical potential of the pro-
tein and is proportional to the solvent-exposed 
surface area of the protein, thus more expanded 
conformations are disfavored in the presence of 
osmolytes and the protein tends to adopt the more 
compact native structure.
38 Recently, Carprnter 
et al. have investigated the effects of sucrose, a 
model osmolyte, on the conformational equilibria 
and ﬂ  uctuations within the native-state ensembles 
of bovine pancreatic ribonuclease A and S and 
horse heart cytochrome c and concluded that the 
presence of sucrose shifts the conformational 
equilibria toward the most compact protein species 
within the native-state ensembles due to the pref-
erential exclusion of sucrose from the protein 
surface.
39
Besides the human diseases and their corre-
sponding therapies mentioned above, lysosomal 
storage diseases have been tested for possible 
chemical chaperone therapy in humans. For 
example, Matsuda et al. have synthesized a 
compound, N-octyl-4-epi-β-valienamine (NOEV), 
for molecular therapy of brain pathology in 
β-galactosidosis and confirmed its restorative 
effect on the model mouse brain after short-term 
oral administration.
40 Moreover, Tropak and co-
workers have shown that increasing the amount of 
hexosaminidase A is capable of exiting the endo-
plasmic reticulum for transport to the lysosome 
and propose that such hexosaminidase inhibitors 
can function as pharmacological chaperones by 
enhancing the stability of the native conformation 
of the enzyme.
41
However, these chemical chaperones are a far 
from practical therapeutic approach in humans 
because the necessary efﬁ  cacious dose is toxic. 
Nevertheless, exploiting the mechanism by which 
they are effective may yield clues for the design of 
new compounds, which are less toxic. For example, 
Zhang et al. have reported that some organic sol-
utes, such as myo-inositol, betaine, and taurine, 
exhibit the ability to restore the folding defect of 
F508del-CFTR.
42 Despite their reduced toxicity in 
comparison to glycerol, the robustness and 
corrective efﬁ  cacy of such compounds remain to 
be demonstrated in the whole organisms. Encourag-
ingly, some in vivo data has already shown that such 
strategy may be valid.
43 Moreover, recent study has 
reported that various disaccharides can inhibit the 
polyglutamine-mediated protein aggregation.
44 
Tanaka et al. have found that trehalose, the most 
effective disaccharides, can decrease polyglutamine 
aggregates in cerebrum and liver due to the 
improved motor dysfunction and extended lifespan 
in a transgenic mouse model of Huntington 
disease.
44 Most importantly, trehalose is nontoxic 
with high solubility and can be coupled with 
efﬁ  cacy upon oral administration, which makes 
trehalose a promising therapeutic drug or a leading 
compound for the treatment of polyglutamine 
diseases.
44 These evidences together suggest that 
chemical chaperones are potential pharmaceuticals 
for the treatment of protein misfolding diseases.
Insights into the Process of Protein 
Misfolding: Computational Studies
Understanding the misfolded structure of the 
amyloid-associated proteins and how they change 
their conformations to the misfolded and/or toxic 
forms can help to elucidate their aggregation 
mechanisms and may contribute to the develop-
ment of some effective therapies for treating PCDs 
in humans. Drug compounds are generally designed 
to inhibit, restore, or otherwise modify the structure 
and behavior of the disease-associated proteins. 
Target proteins are typically the key molecules 
involved in a speciﬁ  c metabolic or cell signaling 
pathway that is known or is believed to be related 
to a particular disease state.
The early stage in drug discovery involves tar-
get discovery, validation, and identiﬁ  cation by 
high-throughput physical and/or virtual screening. 
So far, structure-based drug design is considered 
as one of the most powerful approaches in drug 
discovery platform and ca be applied computation-
ally when the structure of the target protein is (i) 
known based on the crystallographic, nuclear 
magnetic resonance (NMR) techniques, or other 
experimental methods, or is (ii) unknown yet to be 
built using homology modeling. The process often 
involves the generation of a very large in silico 
library of potential derivatives and the use of 
molecular docking to select derivatives that may 
interact with the target protein on the basis of shape 
complementarities and charge placement.46
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However, the critical problem is the structural 
information about the target protein must be avail-
able. Unfortunately, due to the difﬁ  culties in crys-
tallizing amyloid fibrils, the detailed intrinsic 
structure has yet to be determined by x-ray diffrac-
tion. Thus, some biophysical techniques, such as 
transmission and cryo-electron microscopy, atomic 
force microscopy (AFM), and solid-state NMR, 
have been used to disclose the structural features 
of amyloid ﬁ  brils. Nevertheless, these techniques 
are still difﬁ  cult to provide structural information 
in atomic detail. For the case of Aβ, some evi-
dences have suggested that Aβ exists as a mixture 
of α-helix, β-sheet, and random coil in aqueous 
solution.
45 However, in ﬂ  uorinated alcohols, such 
as triﬂ  uoroethanol (TFE) or hexﬂ  uoro 2-propanol 
(HFIP), it adopts a stable α-helical conformation.
46 
It is known that the α-helical conformation of Aβ 
is temperature sensitive but its β-sheet conforma-
tion is not. Moreover, the α-helical conformation 
of Aβ is favored at pHs 1–4 and 7–10; whereas the 
β-sheet conformation of Aβ is favored at pH 4–7.
47 
X-ray diffraction analyses and NMR determina-
tions have reported that Aβ stacks in the form of 
pleated β-sheet structures oriented perpendicular 
to the ﬁ  bril axis.
48 Furthermore, several conforma-
tional studies on Aβ ﬁ  brillogenesis have suggested 
that the conformational transition of Aβ into 
β-sheet structure in ﬁ  brils goes through an α-helix-
containing intermediate conformation.
49 Thus, it 
is extraordinarily difﬁ  cult to design an inhibitor 
due to the structural complexity of Aβ. Therefore, 
computational studies provide an alternative tool 
to elucidate the transition between the unaggre-
gated and aggregated proteins, where experimental 
techniques cannot yet probe.
Molecular dynamics (MD) simulation has been 
employed as a powerful tool to provide structural 
information in atomic detail under various condi-
tions. For the case of Aβ, numbers of MD simula-
tions have been performed by several groups with 
a view to elucidating the conformational transi-
tion and assembly mechanism based on the mod-
eled structures of Aβ, i.e. fragments or synthesized 
analogs of Aβ. For example, Klimov and 
Thirumalai have performed a series of MD simu-
lations towards Aβ peptide and their results 
showed that Aβ16–22 peptides form antiparallel 
β-sheet structures and the α-helical intermediates 
are transiently populated.
50 They further proposed 
that ﬁ  bril formation by Aβ peptides, which occurs 
by maximizing the number of slat bridges and 
hydrophobic interactions, must involve oligomers 
with high α-helical content. In a more recent 
study, atomic detail MD simulations with explicit 
solvent have been conducted to show that only 
large Aβ16–22 oligomers with at least 8–16 mono-
mers form a stable β-sheet aggregate through 
better hydrophobic contacts and a better shielding 
of backbone-backbone hydrogen bonds from the 
solvent.
51 In the case of prion, two 10-ns trajec-
tories generated by MD simulations have been 
used to probe the initial events in the conforma-
tional transition of PrP
C to the aberrant aggregation-
prone form.
52 More recently, DeMarco and 
Daggeat have simulated the fragment of human 
prion protein (residues 90–230) at low pH, which 
triggers misfolding of this protein, and observed 
a conformational transition to a PrP
SC-like iso-
form.
53 Their results further demonstrated that the 
N-terminal portion of this protein, which has been 
identiﬁ  ed as a probable aggregation site, under-
goes extensive conformational rearrangement, 
leading to the formation of a large solvent-
accessible hydrophobic cluster.
In addition to prion protein and Aβ peptide, 
other amyloid-associated proteins have also been 
investigated intensively by MD simulations. For 
example, TTR has been shown to be the cause of 
or involved in senile systemic amyloidosis.
54 From 
the MD simulation results, Armen et al. have 
proposed that the formation of the “α-sheet” 
structure by alternating αL and αR residues may 
represent a key pathological conformation during 
amyloidogenesis.
55 Another case is human cystatin 
C (HCC), which is thought to co-localize with Aβ 
peptide in the dimeric or oligomeric form in brain 
amyloid deposits of patients, particularly in elderly 
individuals and patients suffering from AD or 
Down’s syndrome.
56 The structure of HCC con-
sists of a core with a ﬁ  ve-stranded anti-parallel 
β-sheet (β-region) wrapped around a central 
helix.
57 The monomeric HCC is thought to form 
a dimeric structure through the so-called “3D 
domain swapping” process.
58 The results from our 
previous MD study has allowed us to propose a 
possible mechanism for HCC domain swapping 
as follows: (i) ﬁ  rst, the central helix departs from 
the β-region via the disruption of the interior 
hydrophobic core (Fig. 2A,B); (ii) subsequently, 
the native contacts within β2 and AS loop disap-
pear (Fig. 2B,C); (iii) then, the β-hairpin between 
β2 and β3 unfolds through the destruction of three 
important salt bridges following the so-called 47
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“zip-up” mechanism (Fig. 2C,D); and (iv) ﬁ  nally, 
the open form of the monomeric HCC is generated 
(Fig. 2E).
59
Most importantly, the results of the above men-
tioned MD simulations are all in good agreement 
with the available experimental observations, pro-
viding atomic insights into the conformational 
changes associated various PCDs in humans and 
may contribute to the development of structure-
based drug design.
Possible Therapeutic Strategies 
for PCDs: Combining MD 
Simulations and Structure-Based 
Drug Design
Recently, a combined approach of MD simulation 
and structure-based drug design was conducted by 
Liu and co-workers.
60 Long time MD simulations 
were conducted to investigate the conformational 
transition of Aβ1–40 and their results showed that Aβ 
adopts a α-helix/β-sheet intermediate structure, 
which exhibits a core domain constituted by the seg-
ment of residues 24–37. In their later study, they 
performed virtual screening based on molecular 
docking towards this Aβ intermediate structure and 
aimed to design inhibitors, which can bind to the 
β-sheet region of the Aβ intermediate to interrupt the 
formation of the pleated β-sheet structure found in 
amyloid fibrils.
55 From the results of thioflavin 
T ﬂ  uorescence assay and AFM determination, they 
have successfully identiﬁ  ed a new inhibitor, named 
as DC-AB1, to abolish Aβ ﬁ  brillation. This study not 
only reveals some clues to understanding the molec-
ular events involved in Aβ aggregation, but also 
provides a strategy for inhibitor design based on the 
ﬂ  exible intermediate structures of Aβ peptides.
From their promising results, we can expect that 
the combined experimental and computational 
approaches to design potential interfering com-
pounds for inhibiting protein aggregation associ-
ated with PCDs in humans will increase dramatically 
in the near future of drug discovery and develop-
ment history.
Conclusions
In this review, we discussed the mechanisms of 
various PCDs in humans, including AD, Prion’s 
disease, and CF, and the strategies of using chem-
ical chaperones and inhibitors as therapeutic agents 
against these diseases. To further understand the 
biological meanings and aggregation mechanisms 
of either amyloid-associated proteins or normal 
proteins with the ability to aggregate into amyloid 
ﬁ  brils, their structures in atomic detail must be 
available. However, the lack of the detailed struc-
tural information of amyloid ﬁ  bril makes it difﬁ  cult 
to elucidate their aggregation mechanisms. At this 
stage, MD simulation combined with some exper-
imental approach may provide a powerful tool to 
gain the atomic insights into the possible 
 
A B C
D E
Figure 2. The proposed mechanism of the 3D domain swapping process of HCC. (A) The closed form of the monomeric HCC;
52 (B) partially 
unfolded monomeric HCC with the central α-helix moving away from the β-region via the disruption of the interior hydrophobic core; (C) 
partially unfolded monomeric HCC with the disappearance of the native contacts between β2 and β3-AS; (D) partially unfolded monomeric 
HCC with the β2-L1-β3 hairpin unfolded following the “zip-up” mechanism; and (E) the open form of the monomeric HCC.
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mechanisms of protein misfolding and aggregation 
associated with a number of PCDs in humans. 
Thus, it may further assist the structure-based drug 
design in the near future of drug discovery and 
development history.
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